Lixisenatide Versus Insulin Glulisine on Fasting and Postbreakfast Systemic Hemodynamics in Type 2 Diabetes Mellitus Patients-Reference-Cited by-同舟云学术

Lixisenatide Versus Insulin Glulisine on Fasting and Postbreakfast Systemic Hemodynamics in Type 2 Diabetes Mellitus Patients

Published:2018-08 Issue:2 Volume:72 Page:314-322
ISSN:0194-911X
Container-title:Hypertension
language:en
Short-container-title:Hypertension

Author:

Tonneijck Lennart¹,Muskiet Marcel H.A.¹,Twisk Jos W.²,Kramer Mark H.H.¹,Danser A.H. Jan³,Joles Jaap A.⁴,Smits Mark M.¹,van Raalte Daniël H.¹

Affiliation:

1. From the Department of Internal Medicine, Diabetes Center (L.T., M.H.A.M., M.H.H.K., M.M.S., D.H.v.R.)

2. Department of Epidemiology and Biostatistics (J.W.T.)

3. VU University Medical Center, Amsterdam, The Netherlands; Division of Pharmacology and Vascular Medicine, Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands (A.H.J.D.)

4. Department of Nephrology and Hypertension, University Medical Center, Utrecht, The Netherlands (J.A.J.).

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Internal Medicine

Reference43 articles.

1. Gastrointestinal actions of glucagon-like peptide-1-based therapies: glycaemic control beyond the pancreas

2. The Cardiovascular Biology of Glucagon-like Peptide-1

3. Renal extraction and acute effects of glucagon-like peptide-1 on central and renal hemodynamics in healthy men

4. Effects of induced hyperinsulinaemia with and without hyperglycaemia on measures of cardiac vagal control

5. Effects of glucagon-like peptide-1, yohimbine, and nitrergic modulation on sympathetic and parasympathetic activity in humans

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Quantified Metrics of Gastric Emptying Delay by Glucagon-Like Peptide-1 Agonists: A Systematic Review and Meta-Analysis With Insights for Periprocedural Management;American Journal of Gastroenterology;2024-05-28

2. The vascular function effects of adding exenatide or meal insulin to basal insulin therapy in early type 2 diabetes;Cardiovascular Diabetology;2023-03-09

3. Current gaps in management and timely referral of cardiorenal complications among people with type 2 diabetes mellitus in the Middle East and African countries: Expert recommendations;Journal of Diabetes;2022-04-17

4. Utilization of glucagon‐like peptide‐1 receptor agonists and changes in clinical characteristics in patients with type 2 diabetes by chronic kidney disease stage in Japan: A descriptive observational study using a nationwide electronic medical records database;Diabetes, Obesity and Metabolism;2021-12-05

5. HEMODYNAMIC EFFECT OF A SINGLE DOSE OF GLUCAGON-LIKE PEPTIDE 1 RECEPTOR (GLP-1R) AGONIST LIRAGLUTIDE IN PATIENTS WITH DIABETIC KIDNEY DISEASE;J PHYSIOL PHARMACOL;2021